Diego Braguglia

Sibylla is an innovative start-up founded in 2017 as a spin-OFF of the INFN (National Institute of Nuclear Physics) and the Trento and Perugia Universities. Its multidisciplinary team of co-founders has developed a pioneering Early Drug Discovery method that applies to the research and design of new drugs, effective against diseases so far incurable. Drug discovery is an extremely complex problem, therefore requiring innovation. Sibylla is a beautiful example of how innovation can be pushed forward by a multidisciplinary and agile team. Sibylla's approach is based on the possibility of simulating the folding pathway from the amino acid sequence as produced by the cells' ribosomes to the native state. Traditional pharmacological methods investigate the target proteins' interaction sites in their native, biologically active state. Novel methods act at the DNA level. Sibylla follows an alternative approach. We identify small molecules that bind to pockets found in the intermediate folding state. These pockets disappear in the native state, and that is why we may try to drug proteins which have been so far considered undruggable. Sibylla technology is called PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting). A molecule found through PPI-FIT would impair the folding of the protein, leading it to degradation. The overall effect is a selective reduction of the expression level of the target protein. The medical areas focused on by Sibylla's research include oncology and antibiotic resistance, although the technology can be applied to any therapeutic area. The company is developing a proprietary pipeline of potential drugs. We can also provide co-development or identifying potential drugs for pharmaceutical companies' specific targets. We recently signed a collaboration agreement with an important Pharma company. Besides the promising results already achieved, Sibylla keeps being engaged in developing proprietary computing technology.

AB2 Bio Ltd. is a research company based out of EPFL INNOVATION PARK, BUILDING B, 4TH FLOOR, Lausanne, Switzerland.

iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone. iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ to treat Treg-driven tumors; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumors. iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. For more information, please visit www.ionctura.com

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare

Amal Therapeutics is a Biotechnology company located in 64 av., de la Roseraie, 1205 Geneva, Switzerland.

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

Genkyotex has become a wholly owned subsidiary of Calliditas and have been delisted from the Euronext stock exchanges. Genkyotex’s lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase 2b/3 design with setanaxib in 318 patients with primary biliary cholangitis (PBC). As previously announced in August 2021, Calliditas received FDA fast track designation for setanaxib in PBC. Calliditas will also initiate a Phase 2 proof-of-concept study in head and neck cancer in 2021, which will investigate the administration of setanaxib in conjunction with immunotherapy targeting cancer associated fibroblasts (CAFs). Follow @Calliditas Therapeutics for updates on future developments: https://www.linkedin.com/company/calliditas-therapeutics/

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has conducted numerous clinical studies and has shown that using contact force during ablation can reduce procedure time (1), as well as PV gaps at 3-month invasive follow-up (2). The company’s flagship product is the TactiCath Quartz®, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Prior to force-sensing – which Endosense pioneered in catheter ablation - the physicians had to estimate the force applied during ablation. If too much force was applied, there was a risk of perforating the heart wall, if too little force was applied, there was a risk of recurrence; the patient needing a second treatment. (1) Force controlled RF ablation increases Effectivity for AF ablation using PV isolation J. Schreieck et al., Tübingen, Germany – Clin Res Cardiol 101, Suppl 1, April 2012, P660 (2) Contact Force, FTI and Lesion continuity are critical to improve durable PV isolation: EFFICAS II results J Kautzner et al. – Heart Rhythm Society, May 2012, Boston USA

CeQur®, a medical device company dedicated to simplifying mealtime insulin delivery for individuals on multiple daily injections, manufactures CeQur Simplicity, a simple-to-use wearable insulin delivery device enabling discreet, convenient and injection-free bolus dosing. In June 2024, the company announced the FDAs recent 510(k) clearance of CeQur Simplicity for an extended wear duration from 3 to 4 days. One CeQur Simplicity 4-day wearable patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, twelve daily mealtime injections over four days. CeQur is headquartered in Horw, Switzerland. Please visit myceqursimplicity.com for more information.

Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life. alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

We are a bio-pharmaceutical company focused on the development of novel antibiotics to combat the evolving threat of bacterial infections in humans and animals. MerLion Pharmaceuticals is located in Berlin-Buch, Germany and manages the non-clinical and clinical development as well as active pharmaceutical ingredient and drug product development and manufacturing. Our pipeline includes the antibiotics finafloxacin and friulimicin.

Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs

Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers. The company is based in Cambridge, Massachusetts.

Neocutis S.A. is a biotechnology company based out of 6 Ch. du Stand, Pully, VD, Switzerland.

Sibylla is an innovative start-up founded in 2017 as a spin-OFF of the INFN (National Institute of Nuclear Physics) and the Trento and Perugia Universities. Its multidisciplinary team of co-founders has developed a pioneering Early Drug Discovery method that applies to the research and design of new drugs, effective against diseases so far incurable. Drug discovery is an extremely complex problem, therefore requiring innovation. Sibylla is a beautiful example of how innovation can be pushed forward by a multidisciplinary and agile team. Sibylla's approach is based on the possibility of simulating the folding pathway from the amino acid sequence as produced by the cells' ribosomes to the native state. Traditional pharmacological methods investigate the target proteins' interaction sites in their native, biologically active state. Novel methods act at the DNA level. Sibylla follows an alternative approach. We identify small molecules that bind to pockets found in the intermediate folding state. These pockets disappear in the native state, and that is why we may try to drug proteins which have been so far considered undruggable. Sibylla technology is called PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting). A molecule found through PPI-FIT would impair the folding of the protein, leading it to degradation. The overall effect is a selective reduction of the expression level of the target protein. The medical areas focused on by Sibylla's research include oncology and antibiotic resistance, although the technology can be applied to any therapeutic area. The company is developing a proprietary pipeline of potential drugs. We can also provide co-development or identifying potential drugs for pharmaceutical companies' specific targets. We recently signed a collaboration agreement with an important Pharma company. Besides the promising results already achieved, Sibylla keeps being engaged in developing proprietary computing technology.

AB2 Bio Ltd. is a research company based out of EPFL INNOVATION PARK, BUILDING B, 4TH FLOOR, Lausanne, Switzerland.

iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone. iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ to treat Treg-driven tumors; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumors. iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. For more information, please visit www.ionctura.com

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare

Amal Therapeutics is a Biotechnology company located in 64 av., de la Roseraie, 1205 Geneva, Switzerland.